TRAX First Tracks Biotherapeutics, Inc.

CIK 0002091349 6 ready 8-Ks latest October 13, 2026, 8:32 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 0 baseline

Ready 8-Ks 6

Latest filing October 13, 2026, 8:32 AM ET

Top materiality 0.80

Event mix other_material ×4 · earnings ×2

Sentiment 2 pos · 0 neg · 4 neu

Recent 8-K filings for TRAX

Highest-materiality recent filing

First Tracks Biotherapeutics completes spin-off from AnaptysBio and raises ~$80M in private placement

April 20, 2026, 7:59 PM ET other material materiality 0.80 neutral item 1.01 item 2.01 item 3.02 item 3.03 item 5.03 item 5.01 item 5.02 item 8.01 item 9.01 ◈ Governance Changes ×2◈ Material Agreements ×2◈ Equity Issuances◈ M&A Transactions

Spin-off effective April 20, 2026; AnaptysBio holders received one First Tracks share per AnaptysBio share held on April 6 record date.
Private placement of ~10.5M shares at $13.81: company issued 5.79M shares (~$80M proceeds) and selling stockholder sold 4.71M shares.

Read filing →

October 13, 2026, 8:32 AM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

First Tracks' ANB033 hits Phase 1b celiac endpoints; Vh:Cd delta +0.49 (p=0.009), IEL density -20.03 (p<0.001)

Vh:Cd LS mean change -0.17 on ANB033 vs -0.66 on placebo (placebo-adjusted +0.49, p=0.009); IEL density -1.20 vs +18.83 (-20.03, p<0.001).
August 12, 2026, 4:19 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

First Tracks Q2 net loss $33.4M, cash $168M; ANB033 Fast Track, Cohort 1 data Q4

Q2 2026 net loss $33.4M ($0.95/share) vs $42.4M ($1.47) year-ago; R&D spend $25.6M.
May 14, 2026, 4:24 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

First Tracks Q1 net loss $50.5M; launched with $180M cash; ANB033 Phase 1b data expected Q4 2026

Net loss of $50.5M for Q1 2026 vs $47.2M in Q1 2025; R&D expense $34.0M (down from $41.5M).
April 20, 2026, 7:59 PM ET other material materiality 0.80 neutral item 1.01 item 2.01 item 3.02 item 3.03 item 5.03 item 5.01 item 5.02 item 8.01 item 9.01 ◈ Governance Changes ×2◈ Material Agreements ×2◈ Equity Issuances◈ M&A Transactions

First Tracks Biotherapeutics completes spin-off from AnaptysBio and raises ~$80M in private placement

Spin-off effective April 20, 2026; AnaptysBio holders received one First Tracks share per AnaptysBio share held on April 6 record date.
April 3, 2026, 7:59 PM ET other material materiality 0.80 neutral item 7.01 item 9.01

First Tracks Biotherapeutics spin-off from AnaptysBio effective April 20; $80M PIPE at $13.81/sh

Spin-off of biopharma assets: holders receive 1 share TRAX per ANAB share held on April 6 record date.

Materiality & sentiment trend

Max materiality 0.80 · Median 0.75 · Most common event other_material

2 positive 0 negative 4 neutral

source · TRAX on sec.gov